| Oral Iptacopan in Paroxysmal Nocturnal Hemoglobinuria |
|
The New England Journal of Medicine |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Oral Iptacopan in Paroxysmal Nocturnal Hemoglobinuria. Reply |
|
The New England Journal of Medicine |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria |
|
The New England Journal of Medicine |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial |
|
The Lancet Haematology |
Myelodysplastic Syndromes (MDS) |
| Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial |
|
The Lancet Haematology |
Myelodysplastic Syndromes (MDS) |
| Paroxysmal nocturnal hemoglobinuria without GPI-anchor deficiency |
|
The Journal of Clinical Investigation |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Updates in low/intermediate-risk MDS |
|
The Hematology, ASH Education Program |
Myelodysplastic Syndromes (MDS) |
| Epidemiology and Pathogenesis of Myelodysplastic Syndrome |
|
The Cancer Journal |
Myelodysplastic Syndromes (MDS) |
| Overview of the Management of Higher-Risk Myelodysplastic Syndromes |
|
The Cancer Journal |
Myelodysplastic Syndromes (MDS) |
| The Management of Low-Risk Myelodysplastic Syndromes-Current Standards and Recent Advances |
|
The Cancer Journal |
Myelodysplastic Syndromes (MDS) |
